Christos Mantzoros, MD, DSc, PhD

Adjunct Professor, Medicine

Christos Mantzoros


Christos S. Mantzoros, MD, DSc, PhD h.c. mult., is a Professor of Medicine at Harvard Medical School and an Adjunct Professor at Chobanian and Avedisian School of Medicine. He has also served as a Professor of Environmental Health at the Harvard School of Public Health. He currently serves as the Chief of Endocrinology, Diabetes and Metabolism at the Boston VA Healthcare System and the Director of the Human Nutrition Unit of the Division of Endocrinology Diabetes and Metabolism at Beth Israel Deaconess Medical Center. Dr. Mantzoros has been the editor of two books (one on “Diabetes and Obesity” and one on “Nutrition and Metabolism” with more than two editions each). His research has resulted in more than 800 publications in Medline, including more than 150 publications under the collaborative Look Ahead Research Group, more than 200 chapters and reviews, with more than 72,000 citations with a Hirsch Index H=121. Dr. Mantzoros is also the director for the VA Boston Healthcare System fellowship program with Boston University Medical Center (BUMC), which offers one dedicated fellowship position through BUMC, but also allows any fellow at BUMC or Harvard affiliated fellowship programs the opportunity to rotate through the VA Boston Healthcare System. He has served as a Board Member or an advisor or head of the Scientific Advisor Board of non for profit foundations as well as governmental and non-governmental entities. He is the Editor-in-Chief of the journal Metabolism and is on the editorial board of several scientific journals worldwide. For his research discoveries and public health service Dr. Mantzoros has received four honorary PhDs, the Alexander Technological Institute of Thessaloniki has named their nutrition laboratories after his name and several Universities worldwide have awarded Dr. Mantzoros honorary Professorships and visiting Professorships. He has or is supervising PhD thesis work in several nations worldwide (Sweden, Germany, Greece, USA etc) and is actively collaborating with many research groups worldwide. He has mentored more than 160 young scientists who currently hold key positions in clinical medicine, academia, industry as well as governmental agencies and nongovernmental organizations. Dr. Mantzoros has been elected a member of ASCI and a Fellow of the American College of Physicians and the American Association of Clinical Endocrinology. He has been given several awards including but not limited to awards by: the American Association of Clinical Endocrinology (Frontiers in Science Award), the American Diabetes Association (Novartis Award in Diabetes and Metabolic Diseases), the North American Association for the Study of Obesity / the Obesity Society (Lilly Award), the American Society for Nutrition (Mead Johnson Award), the HypoCCS award in Paris, France, the Humboldt Foundation of Germany (the Wilhelm Friedrich Bessel Award), by the American Federation of Medical Research (the Outstanding Investigator Award), by the American Physiological Society (FASEB, the Berson Award Lecture), by the New England Hellenic Medical and Dental Association (Hygeia award) etc. He has also received the BIDMC, Harvard Medical School, award for excellence in Mentoring. He will be receiving the 2018 European Society of Endocrinology Geoffrey Harris Prize.

Other Positions

  • Professor, Medicine, Harvard Medical School
  • Director, Human Nutrition Unit, Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center
  • Endocrinology, VA Boston Healthcare System


  • University of Athens, MD
  • University of Athens, DSc
  • Harvard Medical School, MMS/MMSc
  • Harvard School of Public Health, MSc


  • Published on 9/25/2023

    Valenzuela-Vallejo L, Chrysafi P, Kouvari M, Guatibonza-Garcia V, Mylonakis SC, Katsarou A, Verrastro O, Markakis G, Eslam M, Papatheodoridis G, Mingrone G, George J, Mantzoros CS. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study. Metabolism. 2023 Sep 25; 148:155694. PMID: 37757973.

    Read at: PubMed
  • Published on 9/7/2023

    Kokkorakis M, Katsarou A, Katsiki N, Mantzoros CS. Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery. Metabolism. 2023 Sep 07; 148:155689. PMID: 37689110.

    Read at: PubMed
  • Published on 8/9/2023

    Kouvari M, Mylonakis SC, Katsarou A, Valenzuela-Vallejo L, Guatibonza-Garcia V, Kokkorakis M, Verrastro O, Angelini G, Markakis G, Eslam M, George J, Papatheodoridis G, Mingrone G, Mantzoros CS. The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study. Diabetes Res Clin Pract. 2023 Sep; 203:110870. PMID: 37567510.

    Read at: PubMed
  • Published on 8/8/2023

    Demir M, Bornstein SR, Mantzoros CS, Perakakis N. Liver fat as risk factor of hepatic and cardiometabolic diseases. Obes Rev. 2023 Oct; 24(10):e13612. PMID: 37553237.

    Read at: PubMed
  • Published on 8/4/2023

    Polyzos SA, Vachliotis ID, Mantzoros CS. Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease. Metabolism. 2023 Oct; 147:155676. PMID: 37544590.

    Read at: PubMed
  • Published on 7/30/2023

    Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Polyzos SA, Deng Y, Kokkorakis M, Agraz M, Mylonakis SC, Katsarou A, Verrastro O, Markakis G, Eslam M, Papatheodoridis G, George J, Mingrone G, Mantzoros CS. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study. Metabolism. 2023 Oct; 147:155666. PMID: 37527759.

    Read at: PubMed
  • Published on 7/28/2023

    Kokkorakis M, Boutari C, Katsiki N, Mantzoros CS. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism. 2023 Oct; 147:155664. PMID: 37517792.

    Read at: PubMed
  • Published on 7/11/2023

    Sahebkar A, Foroutan Z, Katsiki N, Jamialahmadi T, Mantzoros CS. Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy? Metabolism. 2023 Sep; 146:155659. PMID: 37442270.

    Read at: PubMed
  • Published on 6/28/2023

    Stefanakis K, Kokkinos A, Simati S, Argyrakopoulou G, Konstantinidou SK, Kouvari M, Kumar A, Kalra B, Mantzoros CS. Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate meals. Clin Nutr. 2023 Aug; 42(8):1369-1378. PMID: 37418844.

    Read at: PubMed
  • Published on 6/23/2023

    Boutari C, DeMarsilis A, Mantzoros CS. Obesity and diabetes. Diabetes Res Clin Pract. 2023 Aug; 202:110773. PMID: 37356727.

    Read at: PubMed

View 665 more publications: View full profile at BUMC

View all profiles